Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Study finds high number of persistent COVID-19 infections in the general population


A new study led by the Big Data Institute at NDM has found persistent COVID-19 infections are surprisingly common, with around one to three in every 100 infections lasting a month or longer.

Rising antimicrobial resistance in enteric fever across 75 countries

Recent findings by the Global Research on Antimicrobial Resistance Project at NDM's Centre for Tropical Medicine and Global Health revealed the resistance patterns for a priority pathogen--also known as typhoid fever--with high mortality and morbidity in resource-constrained settings.

R21 malaria vaccine phase III trial confirms high efficacy and safety


The phase III trial data results of the R21/Matrix-M vaccine, developed by the Jenner Institute and the Serum Institute of India have confirmed high efficacy and supported regulatory approvals and licensure in several African countries.

World Cancer Day 2024: Highlighting cancer research at the MRC WIMM


This World Cancer Day, we heard from four Group Leaders at the MRC Weatherall Institute of Molecular Medicine about their work and how their groups are helping in the fight against cancer.

AI-based method provides insights for predicting colorectal cancer outcomes


The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.

Study uncovers how the Hepatitis B virus adapts


A new hepatitis B study reveals how viruses adapt to low-oxygen environments, such as those found deep within the liver, opening up possible new therapeutic targets for liver pathogens. NDM researchers have identified hypoxia-inducible factors (HIFs) playing an important role in the regulation of editing of viral RNAs in low oxygen conditions.

UK minister meets with Oxford pandemic researchers


Researchers at the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute hosted the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.

Research into ancient DNA sheds new light on cause of Multiple Sclerosis and other neurodegenerative diseases

Research led by scientists at the Universities of Oxford, Cambridge, Copenhagen, Bristol and California (Berkeley) reveals the evolutionary origins of multiple sclerosis (MS). This new insight into the genetic architecture of this disease changes scientists’ view of its causes and has implications for its treatment, as well as paving the way for further investigations into other diseases.

MORU leads study testing a single pill for drug-resistant malaria in Africa and Asia


To boost the fight against drug-resistant malaria parasites now emerging in Africa, researchers at the Mahidol Oxford Tropical Medicine Research Unit will study the safety and efficacy of a fixed-dose combination (FDC) containing three antimalarial drugs currently given to patients separately in a triple artemisinin-based combination therapy (TACT) cocktail.

VALIDATE network receives Medical Research Council grant


An international network of researchers, led by NDM’s Professor Helen McShane and Professor Samantha Sampson from Stellenbosch University, has recently been awarded a new UK Medical Research Council (MRC) grant to continue the network activities until 2027.

Oxford Vaccine Group, Department of Paediatrics, University of Oxford receives £7.8 million in research funding to fight pandemic and epidemic threats

Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential. The awards will fund research into vaccines against: Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.

£4.3m boost for Oxford-Glasgow spinout tackling antimicrobial resistance

Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised £4.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria.

Single cell spatial analysis provides new insight into immune-pathology in Covid-19 lungs

A Nature Communications study led by Professor Ling-Pei Ho’s group in the MRC Translational Immune Discovery Unit (TIDU) provides new insights into how immune cells interact in the lungs of patients with severe COVID-19.

New discovery furthers our understanding of how critical immune cells are controlled during an infection


A recent publication from Research from the Gerard Lab in Kennedy Institute of Rheumatology looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.

Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines


This study will test the responses of cells in lymph nodes before and after immunisation with flu and COVID-19 vaccines and compare reactions in older and younger adults

Understanding how lipids influence immune responses


In a study, recently published in the Cell, an international team of scientists, including CAMS Oxford Institute (COI) group leaders Professor Graham Ogg and Dr Yi-Ling Chen, has developed a method for simultaneously detecting thousands of lipid molecules that are displayed to T cells in the human immune system.

Tao Dong appointed the Brigitte (Ita) Askonas Professor of Translational Immunology


With effect from 1st May 2023, Professor Tao Dong, has been appointed the Brigitte (Ita) Askonas Professor of Translational Immunology.

Newly discovered cells could be responsible for atherosclerosis complications


A new type of macrophages recently identified in atherosclerotic lesions could provide a missing link in understanding the inflammatory origins of the common yet fatal condition.

Load More